Mutation Profile of Thymic Carcinoma and Thymic Neuroendocrine Tumor by Targeted Next-generation Sequencing
- 1 December 2020
- journal article
- research article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 22 (2), 92-99.e4
- https://doi.org/10.1016/j.cllc.2020.11.010
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 30 references indexed in Scilit:
- Thymoma and thymic carcinoma in the target therapies eraCancer Treatment Reviews, 2013
- Thymic Malignancies: From Clinical Management to Targeted TherapiesJournal of Clinical Oncology, 2011
- Thymic Tumors: Relevant Molecular Data in the ClinicJournal of Thoracic Oncology, 2010
- Expression and Mutational Status of c-kit in Thymic Epithelial TumorsJournal of Thoracic Oncology, 2010
- Sequencing technologies — the next generationNature Reviews Genetics, 2009
- Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and ThymomasClinical Cancer Research, 2009
- Mutational status of EGFR and KIT in thymoma and thymic carcinomaLung Cancer, 2008
- Thymic Carcinoma with Overexpression of MutatedKITand the Response to ImatinibThe New England Journal of Medicine, 2004
- Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinaseProceedings of the National Academy of Sciences of the United States of America, 2003
- The protein tyrosine kinase family of the human genomeOncogene, 2000